180 related articles for article (PubMed ID: 28994041)
1. Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction.
Koizumi Y; Furuya D; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Hematol; 2018 Feb; 107(2):230-234. PubMed ID: 28994041
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
3. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
[TBL] [Abstract][Full Text] [Related]
6. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Relationship between Wilms' Tumor Gene (WT1) Expression in Peripheral Blood of Acute Leukemia Patients and Serum IL-12 and C3 Levels.
Rezai O; Khodadadi A; Heike Y; Mostafai A; Gerdabi ND; Rashno M; Abdoli Z
Asian Pac J Cancer Prev; 2015; 16(16):7303-7. PubMed ID: 26514528
[TBL] [Abstract][Full Text] [Related]
8. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
Tamaki H; Mishima M; Kawakami M; Tsuboi A; Kim EH; Hosen N; Ikegame K; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Osumi K; Soma T; Oji Y; Oka Y; Kawase I; Sugiyama H; Ogawa H
Int J Hematol; 2003 Nov; 78(4):349-56. PubMed ID: 14686494
[TBL] [Abstract][Full Text] [Related]
9. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.
Kitamura K; Nishiyama T; Ishiyama K; Miyawaki S; Miyazaki K; Suzuki K; Masaie H; Okada M; Ogawa H; Imai K; Kiyoi H; Naoe T; Yokoyama Y; Chiba S; Hata T; Miyazaki Y; Hatta Y; Takeuchi J; Nannya Y; Kurokawa M; Ueda Y; Koga D; Sugiyama H; Takaku F
Int J Hematol; 2016 Jan; 103(1):53-62. PubMed ID: 26520650
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission.
Asgarian Omran H; Shabani M; Vossough P; Sharifian R; Tabrizi M; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Leuk Lymphoma; 2008 Feb; 49(2):281-90. PubMed ID: 18231915
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
15. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
[TBL] [Abstract][Full Text] [Related]
16. The significance of detecting WT1 expression in childhood acute leukemias.
Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
18. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.
Menssen HD; Renkl HJ; Rodeck U; Maurer J; Notter M; Schwartz S; Reinhardt R; Thiel E
Leukemia; 1995 Jun; 9(6):1060-7. PubMed ID: 7596170
[TBL] [Abstract][Full Text] [Related]
19. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
Nowakowska-Kopera A; Sacha T; Florek I; Zawada M; Czekalska S; Skotnicki AB
Leuk Lymphoma; 2009 Aug; 50(8):1326-32. PubMed ID: 19811333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]